Track ImmunoPrecise Antibodies's PP&E ($4.1M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (January 2026), IPA shows a PP&E of $4.1M. That compares with $16M in the prior-year period — down 74.0% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, IPA's PP&E is now $4.1M (was $16M) — a 74.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether ImmunoPrecise Antibodies is outperforming or lagging.
Tracking IPA's property, plant & equipment over time shows whether ImmunoPrecise Antibodies is scaling, shrinking, or reshaping that part of the business. The current reading is $4.1M That compares with $16M in the prior-year period — down 74.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this property, plant & equipment page, Stockcircle has ImmunoPrecise Antibodies's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect PP&E (currently $4.1M) with ownership activity and broader fundamentals.
ImmunoPrecise Antibodies's PP&E is $4.1M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.